CRSP — Crispr Therapeutics AG Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $3.20bn
- $3.51m
Brief: Crispr Therapeutics Strengthens Executive Leadership Team With Key Appointments
Brief: Crispr Therapeutics Provides Business Update
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments (updated)
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
bluebird up on first outcomes-based Medicaid agreement for sickle cell gene therapy
Analysis: Prices for new US drugs rose 35% in 2023, more than the previous year
CRISPR Therapeutics rises on upbeat quarterly profit
CRISPR Therapeutics rises on upbeat quarter
Swiss stocks - Factors to watch on February 19
Brief: Crispr Therapeutics AG To Sell About $280 Million Of Its Common Shares
Brief: CRISPR Says European Commission Approves First Crispr/Cas9 Gene-Edited Therapy, Casgevy For Treatment Of Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia
Swiss stocks - Factors to watch on January 17
Brief: CRISPR Therapeutics Announces U.S. FDA Approval of CASGEVY (exagamglogene autotemcel) For The Treatment of Transfusion-Dependent Beta Thalassemia
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder (updated)
Brief: Ark Investment Management LLC Reports 10.75% Passive Stake In CRISPR Therapeutics As Of Dec 31, 2023 Versus 10.16% As Of March 31, 2023 - SEC Filing
Brief: Crispr Therapeutics Highlights Strategic Priorities And 2024 Outlook
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery
Some US gene therapy developers set to end 2023 on a high